Skip to main content

Meet CeMM at BIO-Europe Digital on 25-28 October 2021

Share

From L to R: Thomas Hannich, Anna Koren, Prudence Donovan, Stefan Kubicek, André Müller and Christoph Bock (© Laura Alvarez / CeMM).

As a pioneering institute with the goal of achieving maximum scientific innovation in molecular medicine to improve healthcare, CeMM is fully committed to identifying, supporting, and developing its research discoveries into impactful solutions for society. In line with this, once again this year on 25-28 October, CeMM will be joining the BIO-Europe Digital conference, the meeting point for global biopharma and investment leaders to build partnerships that facilitate innovation and medical breakthroughs. 

CeMM IP and Technology Transfer Manager, Prudence Donovan, together with the heads of CeMM services and facilities, Christoph Bock, Stefan Kubicek, Thomas Hannich, Anna Koren and André Müller, see BIO-Europe as an excellent forum to complement CeMM’s objective to promote and achieve improvements to healthcare through innovation.

CeMM’s participation at BIO-Europe is a strategic networking and partnership opportunity, it is a unique forum where key innovation stakeholders come together under one virtual roof. We look forward to engaging in critical dialogue with industry. Our goal is to identify industry partners with a mutual interest to develop CeMM inventions into products and services that will transform healthcare and benefit society”, says Prudence Donovan.

CeMM is looking for strategic partners

CeMM is actively seeking partners for a new breakthrough diagnostic medical imaging technology and a novel therapeutic for hyperlipidemia. We are also actively seeking pharmaceutical companies interested in increasing the efficiency of their drug screens using our novel high-throughput sequencing technology, scifi-RNA-seq.

Presenting CeMM Facilities – From genes to drugs

At our CeMM Facilities, we use a technology-driven approach to offer our customers the discovery and characterization of such bioactive molecules, including proteins, metabolites, and novel synthetic compounds. CeMM is looking for strategic partners to engage in our full-service Biomedical Sequencing Facility (BSF) and Molecular Discovery Platform.

Request a partnering meeting with us

If you are looking for innovations in medical imaging, novel therapeutics and high-throughput molecular discovery platforms, meet us at BIOEurope. Partnering opens on 20 September 2021, request a meeting with us via this link.

We are looking forward to engaging with all interested partners and companies and discussing the possibility of new partnership options at the digital event!

For any questions, please contact CeMM IP & Tech Transfer Manager Prudence Donovan.